GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amphastar Pharmaceuticals Inc (NAS:AMPH) » Definitions » ROE %

Amphastar Pharmaceuticals (Amphastar Pharmaceuticals) ROE % : 23.44% (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Amphastar Pharmaceuticals ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Amphastar Pharmaceuticals's annualized net income for the quarter that ended in Dec. 2023 was $144.7 Mil. Amphastar Pharmaceuticals's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was $617.3 Mil. Therefore, Amphastar Pharmaceuticals's annualized ROE % for the quarter that ended in Dec. 2023 was 23.44%.

The historical rank and industry rank for Amphastar Pharmaceuticals's ROE % or its related term are showing as below:

AMPH' s ROE % Range Over the Past 10 Years
Min: -4.01   Med: 2.12   Max: 23.71
Current: 23.71

During the past 13 years, Amphastar Pharmaceuticals's highest ROE % was 23.71%. The lowest was -4.01%. And the median was 2.12%.

AMPH's ROE % is ranked better than
92.3% of 1000 companies
in the Drug Manufacturers industry
Industry Median: 4.335 vs AMPH: 23.71

Amphastar Pharmaceuticals ROE % Historical Data

The historical data trend for Amphastar Pharmaceuticals's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amphastar Pharmaceuticals ROE % Chart

Amphastar Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.71 0.36 14.65 18.76 23.55

Amphastar Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 26.24 19.33 18.37 33.25 23.44

Competitive Comparison of Amphastar Pharmaceuticals's ROE %

For the Drug Manufacturers - Specialty & Generic subindustry, Amphastar Pharmaceuticals's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amphastar Pharmaceuticals's ROE % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Amphastar Pharmaceuticals's ROE % distribution charts can be found below:

* The bar in red indicates where Amphastar Pharmaceuticals's ROE % falls into.



Amphastar Pharmaceuticals ROE % Calculation

Amphastar Pharmaceuticals's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=137.545/( (528.658+639.421)/ 2 )
=137.545/584.0395
=23.55 %

Amphastar Pharmaceuticals's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Sep. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=144.668/( (595.14+639.421)/ 2 )
=144.668/617.2805
=23.44 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.


Amphastar Pharmaceuticals  (NAS:AMPH) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=144.668/617.2805
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(144.668 / 712.42)*(712.42 / 1528.7725)*(1528.7725 / 617.2805)
=Net Margin %*Asset Turnover*Equity Multiplier
=20.31 %*0.466*2.4766
=ROA %*Equity Multiplier
=9.46 %*2.4766
=23.44 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=144.668/617.2805
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (144.668 / 165.38) * (165.38 / 215.92) * (215.92 / 712.42) * (712.42 / 1528.7725) * (1528.7725 / 617.2805)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.8748 * 0.7659 * 30.31 % * 0.466 * 2.4766
=23.44 %

Note: The net income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Amphastar Pharmaceuticals ROE % Related Terms

Thank you for viewing the detailed overview of Amphastar Pharmaceuticals's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Amphastar Pharmaceuticals (Amphastar Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
11570 6th Street, Rancho Cucamonga, CA, USA, 91730
Amphastar Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the company sells insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has two reportable segments finished pharmaceutical products and API products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.
Executives
Mary Z. Luo director, 10 percent owner, officer: COO and Chief Scientist 11570 6TH STREET, RANCHO CUCAMONGA CA 91730
Floyd F. Petersen director 11570 6TH STREET, RANCHO CUCAMONGA CA 91730
Rong Zhou officer: EVP, Production C/O AMPHASTAR PHARMACEUTICALS INC., 11570 SIXTH STREET, RANCHO CUCAMONGA CA 91730
Richard K Prins director
William J Peters officer: CFO, SVP & Treasurer C/O AMPHASTAR PHARMACEUTICALS, INC., 11570 6TH STREET, RANCHO CUCAMONGA CA 91730
Yakob Liawatidewi officer: SVP Corp Admin Center C/O AMPHASTAR PHARMACEUTICALS INC, 11570 SIXTH STREET, RANCHO CUCAMONGA CA 91730
Michael A Zasloff director
Gayle Deflin director 11570 6TH STREET, RANCHO CUCAMONGA CA 91730
Diane G. Gerst officer: EVP, QA & Regulatory Affairs 11570 6TH STREET, RANCHO CUCAMONGA CA 91730
Howard Lee director 13F-2, NO. 36, LANE 48, SECTION 3, NAN-JING EAST ROAD, TAIPEI, TAIWAN F4 00000
Jack Y. Zhang director, 10 percent owner, officer: CEO & Chief Scientific Officer 11570 6TH STREET, RANCHO CUCAMONGA CA 91730
David Maris director C/O AMPHASTAR PHARMACEUTICALS, INC., 11570 6TH STREET, RANCHO CUCAMONGA CA 91730
Richard Koo director 11570 6TH STREET, RANCHO CUCAMONGA CA 91730
Jason B. Shandell director, officer: President 11570 6TH STREET, RANCHO CUCAMONGA CA 91730
Applied Physics & Chemistry Laboratories, Inc. 10 percent owner 13760 MAGNOLIA AVENUE, CHINO CA 91710